Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT‑ION): an open‑label, single‑arm, phase 2 trial
Three-year adjuvant imatinib did not significantly improve recurrence‑free survival or overall survival of the patients with rupture compared with 1‑year treatment, but in the largest mutational subset with KIT exon 11 deletion/indel mutation overall survival was higher in the 3‑year group than in the 1‑year group (10‑year OS 94% vs. 54%).
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Disproportionality analysis of adverse events associated with tyrosine kinase inhibitors in gastrointestinal stromal tumors in the FDA adverse event reporting system
- Review of Genomic Testing and SDH Deficiency in Gastrointestinal Stromal Tumors: Getting to the GIST
- Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives
- Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach
- UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST)